OTCPK:HALB - Post by User
Post by
AveragePennyon Dec 20, 2021 10:19am
41 Views
Post# 34246622
Halberd Moves Closer to Proving Its Patented Technologies
Halberd Moves Closer to Proving Its Patented Technologies JACKSON CENTER, PA / ACCESSWIRE / December 20, 2021 / Halberd Corporation (OTC Pink:HALB) has been able to successfully eliminate Interleukin-2 (IL-2) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Halberd also successfully replicated its previous successful elimination of each of the inflammatory cytokines listed as complete in the table below. Interleukin-2 is a pro-inflammatory cytokine whose role in Alzheimer's Disease is not very well established, particularly given the multiplicity of bio factors implicated in this devastating disease. It may cause neurodegeneration as well as provide neuroprotection, depending on the level. Maintaining the appropriate level of IL-2, and other inflammatory cytokines in CSF is critical to neuro-health.
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "The ability to precisely control the exact level of IL-2 in cerebrospinal fluid may be another important step in halting the progression of Alzheimer's Disease; especially when this ability is combined with the precise control of the concentrations of phosphorylated- Tau, beta-Amyloid and other contributing inflammatory cytokines."
https://www.accesswire.com/678515/halberd-moves-closer-to-proving-its-patented-technologies-eliminate-contributors-to-neurodegenerative-diseases